Introduction And Core Principles

  • Extracorporeal membrane oxygenation is a highly advanced, life-sustaining modification of cardiopulmonary bypass providing prolonged cardiac and respiratory support.
  • Functions as a temporizing measure acting as a bridge to recovery, destination therapy, or cardiopulmonary transplantation.
  • Deoxygenated venous blood is drained using a centrifugal pump, passed through a polymethylpentene oxygenator for gas exchange, warmed, and returned to the patient.
  • The application has shifted from a salvage therapy of last resort to a preemptive, protocolized intervention.

Modalities Of Extracorporeal Support

ModalityPhysiological SupportClinical Characteristics And Recent Advances
Veno-Venous (VV)Exclusive respiratory supportRelies on native cardiac output; modern practice favors single-site, double-lumen cannulas to improve patient mobility and reduce decannulation risk.
Veno-Arterial (VA)Full hemodynamic and respiratory supportBypasses heart and lungs to unload ventricles; modality of choice for cardiogenic shock and myocarditis.
Hybrid (VVA/VP)Targeted cardiorespiratory supportVeno-Veno-Arterial (VVA) optimizes upper body oxygenation; Veno-Pulmonary (VP) directly addresses isolated right ventricular failure.

Clinical Indications And Contraindications

Primary Indications

  • Respiratory indications include severe acute respiratory distress syndrome, refractory viral pneumonias, meconium aspiration syndrome, and congenital diaphragmatic hernia.
  • Cardiac indications feature fulminant viral myocarditis, acute decompensated heart failure, and complex congenital heart disease.
  • Extracorporeal cardiopulmonary resuscitation deployed within 30 to 45 minutes of refractory cardiac arrest yields significantly higher neurologically intact survival.

Contraindications

  • Absolute contraindications include lethal chromosomal anomalies, severe irreversible brain injury, massive intracranial hemorrhage, and terminal malignancies.
  • Extreme prematurity (less than 34 weeks gestation) or weight less than 2 kilograms remain strong relative contraindications due to the high risk of catastrophic intraventricular hemorrhage from systemic anticoagulation.

Recent Technological And Pharmacological Advances

Circuit Innovations

  • Polymethylpentene hollow-fiber oxygenators eliminate plasma leak, lower resistance, and extend functional lifespans, reducing inflammatory responses.
  • Biomimetic circuit coatings with nitric oxide-releasing polymers significantly blunt the contact activation of the coagulation cascade and systemic inflammatory response syndrome.
  • Magnetically levitated centrifugal pumps drastically reduce shear stress, resulting in decreased circuit-induced hemolysis and subsequent acute kidney injury.

Anticoagulation Shift

  • Massive pharmacological shift is occurring from unfractionated heparin to Bivalirudin.
  • Bivalirudin provides predictable anticoagulation and is associated with a marked reduction in major hemorrhagic complications.
  • Routine supplementation with Factor XIII concentrate is actively employed to mitigate refractory surgical site and mucosal hemorrhage during prolonged runs.

ELSO Guidelines And Survivorship Programs

ELSO 2025-2026 Guidelines

  • Mandates continuous multimodal neuromonitoring utilizing Near-Infrared Spectroscopy, serial transcranial dopplers, and continuous electroencephalography.
  • Promotes early, cautious trophic enteral feeds even with high inotrope scores to prevent gut mucosal atrophy and bacterial translocation.

Mobile Transport And Survivorship

  • Primary retrieval utilizes specialized mobile teams utilizing miniaturized transport consoles to stabilize and transport the child back to apex centers.
  • Up to 30% of pediatric survivors suffer from Post-Intensive Care Syndrome.
  • Institutions utilize the Standardized Therapy after ECMO Program (STEP) for intentional, multidisciplinary discharge and longitudinal neurodevelopmental follow-up.